Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?

TheMotleyFool

0 0

Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?

Merck (NYSE: MRK) and its partner, Ridgeback Biotherapeutics, hope to soon win U.S. Emergency Use Authorization (EUA) for the first COVID-19 pill. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss the potential impact of Merck's pill on COVID-19 antibody therapies.

Source Fool.com

Like: 0

MRK

Share